// App-Quantinova.ai

706 : NOUS-PEV, a novel personalized viral-based prime/boost cancer immunotherapy targeting patient-specific neoantigens: interim results from the first subjects in the phase 1b study

Researchers

Presenter

  • Oliver Bechter

Principal Investigators

  • Juan Martin-Liberal

  • Anna D’Alise

  • Guido Leoni

  • Gabriella Cotugno

  • Loredana Siani

  • Rosa Vitale

  • Valentino Ruzza

  • Elisa Micarelli

  • Irene Garzia

  • Thea Faivre

  • Sven Gogov

  • Patricia Delaite

  • Stefano Colloca

  • Maria Ambrosio

  • Rossella Merone

  • Elisa Scarselli

  • Stefan Symeonides

Medical Centers

  • Nouscom Srl, Rome, Italy

  • Reithera Srl, Roma, Italy

  • Leuven Cancer Institute, KU Leuven, Leuven, Belgium

  • Edinburgh Cancer Centre, Edinburgh, UK

  • Catalan Institute of Oncology, Badalona, Spain

  • Nouscom AG, Basel, Switzerland

Locations

  • Italy

  • Belgium

  • United Kingdom

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Melanoma

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT04990479

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved